Katerina Machová Poláková

Summary

Affiliation: Institute of Hematology and Blood Transfusion
Country: Czech Republic

Publications

  1. doi request reprint High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain
    Katerina Machova Polakova
    Institute of Hematology and Blood Transfusion, Prague, Czech Republic
    Leuk Res 32:1236-43. 2008
  2. pmc Role of epigenetics in chronic myeloid leukemia
    Katerina Machová Poláková
    Institute of Hematology and Blood Transfusion, U Nemocnice 1, Prague 2, 128 20, Czech Republic
    Curr Hematol Malig Rep 8:28-36. 2013
  3. pmc Expression patterns of microRNAs associated with CML phases and their disease related targets
    Katerina Machová Poláková
    Institute of Hematology and Blood Transfusion, Prague, U Nemocnice 1, 128 20, Czech Republic
    Mol Cancer 10:41. 2011
  4. doi request reprint Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis
    Katerina Machova Polakova
    Institute of Hematology and Blood Transfusion, Department of Molecular Genetics, Prague, Czech Republic
    Exp Hematol 38:20-6. 2010
  5. ncbi request reprint The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR
    Jana Rulcova
    Institute of Hematology and Blood Transfusion, Prague, Czech Republic
    Leuk Res 31:483-91. 2007
  6. doi request reprint Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery
    Hana Klamova
    Institue of Hematology and Blood Transfusion, U Nemocnice 1, 12820 Prague, Czech Republic
    Leuk Res 33:1567-9. 2009
  7. doi request reprint Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs
    Tereza Lopotová
    Institute of Hematology and Blood Transfusion, Department of Cellular Biochemistry, U Nemocnice 1, 128 20, Prague 2, Czech Republic
    Blood Cells Mol Dis 49:41-7. 2012
  8. ncbi request reprint Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase
    Jana Moravcova
    Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Praha 2, Czech Republic
    Leuk Res 28:415-9. 2004
  9. ncbi request reprint Complex chromosomal rearrangements in patients with chronic myeloid leukemia
    Libuse Babicka
    Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and 1st Medical Faculty, Charles University, U nemocnice 2, 128 08 Prague 2, Prague, Czech Republic
    Cancer Genet Cytogenet 168:22-9. 2006
  10. doi request reprint CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma
    Ota Fuchs
    Institute of Hematology and Blood Transfusion, Department of Cell Physiology, U Nemocnice 1, 128 20 Prague 2, Czech Republic
    Blood Cells Mol Dis 40:401-5. 2008

Collaborators

Detail Information

Publications15

  1. doi request reprint High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain
    Katerina Machova Polakova
    Institute of Hematology and Blood Transfusion, Prague, Czech Republic
    Leuk Res 32:1236-43. 2008
    ..HRM results of 100/101 samples were concordant with sequencing data. We found HRM as a suitable and sensitive method for initial rapid screening of BCR-ABL KD mutations to sequence only positive samples...
  2. pmc Role of epigenetics in chronic myeloid leukemia
    Katerina Machová Poláková
    Institute of Hematology and Blood Transfusion, U Nemocnice 1, Prague 2, 128 20, Czech Republic
    Curr Hematol Malig Rep 8:28-36. 2013
    ..Regulatory events at the levels of gene regulation by transcription factors and microRNAs are discussed in the context of CML pathogenesis and therapeutic modalities...
  3. pmc Expression patterns of microRNAs associated with CML phases and their disease related targets
    Katerina Machová Poláková
    Institute of Hematology and Blood Transfusion, Prague, U Nemocnice 1, 128 20, Czech Republic
    Mol Cancer 10:41. 2011
    ..The functions of in silico filtered targets are in this report annotated and discussed in relation to CML pathogenesis...
  4. doi request reprint Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis
    Katerina Machova Polakova
    Institute of Hematology and Blood Transfusion, Department of Molecular Genetics, Prague, Czech Republic
    Exp Hematol 38:20-6. 2010
    ..Median follow-up of unchanged BCR-ABL transcript level was 12 months (range, 6 - 64). We tested this group of patient for BCR-ABL mutations to reveal resistance development and to evaluate the risk of disease progression...
  5. ncbi request reprint The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR
    Jana Rulcova
    Institute of Hematology and Blood Transfusion, Prague, Czech Republic
    Leuk Res 31:483-91. 2007
    ..The results showed B2M as a very convenient CG for BCR-ABL monitoring. On the contrary, the widely used total-ABL was not confirmed as appropriate for normalization of gene expression in CML...
  6. doi request reprint Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery
    Hana Klamova
    Institue of Hematology and Blood Transfusion, U Nemocnice 1, 12820 Prague, Czech Republic
    Leuk Res 33:1567-9. 2009
    ..After delivery four patients achieved partial cytogenetic response on imatinib and two patients achieved major molecular response after crossover to dasatinib...
  7. doi request reprint Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs
    Tereza Lopotová
    Institute of Hematology and Blood Transfusion, Department of Cellular Biochemistry, U Nemocnice 1, 128 20, Prague 2, Czech Republic
    Blood Cells Mol Dis 49:41-7. 2012
    ..Comparison of WT1 variant expression in AML and CML patients' groups differing in response to therapy suggested possible importance of particular WT1 variant levels as markers of further disease course...
  8. ncbi request reprint Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase
    Jana Moravcova
    Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Praha 2, Czech Republic
    Leuk Res 28:415-9. 2004
    ..It is summarized that BCR-ABL transcript kinetics clearly characterize responses to imatinib treatment and are highly predictive for disease progression...
  9. ncbi request reprint Complex chromosomal rearrangements in patients with chronic myeloid leukemia
    Libuse Babicka
    Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and 1st Medical Faculty, Charles University, U nemocnice 2, 128 08 Prague 2, Prague, Czech Republic
    Cancer Genet Cytogenet 168:22-9. 2006
    ..Precise determination of breakpoints involved in CCR can give new dimension to the understanding of genetic mechanisms which play role in progression of malignant disease...
  10. doi request reprint CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma
    Ota Fuchs
    Institute of Hematology and Blood Transfusion, Department of Cell Physiology, U Nemocnice 1, 128 20 Prague 2, Czech Republic
    Blood Cells Mol Dis 40:401-5. 2008
    ..1%) of multiple myeloma (MM) patients' samples. No C/EBPalpha mutations were detected in healthy donors (41 individuals). We discuss how these mutations can affect the cellular function of C/EBPalpha and block the myeloid differentiation...
  11. ncbi request reprint To the intranucleolar translocation of AgNORs in leukemic early granulocytic and plasmacytic precursors
    Karel Smetana
    Institute of Hematology and Blood Transfusion, U Nemocnice 1, Prague 2, 128 20, Czech Republic
    Histochem Cell Biol 125:165-70. 2006
    ..However, more studies in this direction are required in the future...
  12. ncbi request reprint Bmi-1 over-expression plays a secondary role in chronic myeloid leukemia transformation
    Michaela Merkerova
    Institute of Hematology and Blood Transfusion, Department of Molecular Genetics, Prague, Unemocnice 1, 128 20 Prague 2, Czech Republic
    Leuk Lymphoma 48:793-801. 2007
    ..Despite the fact that Bmi-1 deregulation occurs in CML and its expression is connected to several oncogenic processes, Bmi-1 seems to play a secondary role in CML transformation...
  13. doi request reprint MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?
    Tereza Lopotová
    Department of Molecular Genetics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
    Leuk Res 35:974-7. 2011
    ..Following our observation of miR-451 downregulation in CML, we further show its relation to BCR-ABL activity. Our data together with current literature indicate a more complex relationship of miR-451 and BCR-ABL in CML...
  14. ncbi request reprint Targeting of gene expression by siRNA in CML primary cells
    Michaela Merkerova
    Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20, Prague 2, Czech Republic
    Mol Biol Rep 34:27-33. 2007
    ..Gene expressions ranged 22-37% that remained from original levels. According to our results, nucleofection appears to be the only suitable non-viral method for siRNA delivery into the hard-to-transfect CML primary cells...
  15. ncbi request reprint Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea
    Hana Bruchova
    Institute of Hematology and Blood Transfusion, Department of Molecular Genetics, Prague, Czech Republic
    Leuk Lymphoma 43:1289-95. 2002
    ..Only in a few genes were significant changes after hydroxyurea administration observed and inter-individual expression differences were rather common...